ライフサイエンスコーパス: primary myelofibrosis

1 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

2 of those with essential thrombocythemia and primary myelofibrosis.

3 cythemia vera, essential thrombocythemia and primary myelofibrosis.

4 have been devised for myelodysplasia and for primary myelofibrosis.

5 era (PV), essential thrombocythemia (ET), or primary myelofibrosis.

6 and 38 years), with a clinical phenotype of primary myelofibrosis.

7 vent in a JAK2-V617F knock-in mouse model of primary myelofibrosis.

8 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

9 (MPL)-negative essential thrombocythemia and primary myelofibrosis.

10 ential thrombocythemia and 88% of those with primary myelofibrosis.

11 of those with essential thrombocythemia and primary myelofibrosis.

12 the prototypical myeloproliferative neoplasm primary myelofibrosis.

13 to determine whether the same held true for primary myelofibrosis.

14 lus) includes 8 risk factors for survival in primary myelofibrosis.

15 ia vera (PV), essential thrombocythemia, and primary myelofibrosis.

16 ythemia vera, essential thrombocythemia, and primary myelofibrosis.

17 or MPL-mutated essential thrombocytemia and primary myelofibrosis, 2 myeloproliferative neoplasms in

18 Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia,

19 hermore, SMRT(mRID) mice develop spontaneous primary myelofibrosis, a chronic, usually idiopathic dis

20 oughly half of essential thrombocythemia and primary myelofibrosis acquire a unique somatic 1849G>T J

21 ations in this update include: patients with primary myelofibrosis and an intermediate-2 or high-risk

22 A 60-year-old man with primary myelofibrosis and GVHD after receiving allogenei

23 the challenges inherent in the management of primary myelofibrosis and presents an opportunity to add

24 dysplastic syndrome, acute myeloid leukemia, primary myelofibrosis, and T- and B-cell acute lymphocyt

25 cythemia vera, essential thrombocythemia and primary myelofibrosis are also caused by activated tyros

26 cythemia vera, essential thrombocytosis, and primary myelofibrosis are clonal disorders arising in a

27 tial thrombocythemia, polycythemia vera, and primary myelofibrosis are mainly caused by cardiovascula

28 cythemia vera, essential thrombocythemia and primary myelofibrosis are myeloproliferative neoplasms (

29 Severe congenital neutropenia as well as primary myelofibrosis are rare in infancy.

30 ythemia vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell disor

31 ntial thrombocytosis, polycythemia vera, and primary myelofibrosis--are acquired, clonal hematopoieti

32 AK2 mutation as essential thrombocytosis and primary myelofibrosis, but erythrocytosis only occurs in

33 In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL m

34 f patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kina

35 f patients with essential thrombocythemia or primary myelofibrosis carry a somatic mutation of the ca

36 oproliferative neoplasms (polycythemia vera, primary myelofibrosis, chronic myeloid leukemia); inflam

37 n be a potential therapeutic target to block primary myelofibrosis disease progression.

38 f of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mec

39 In particular, contributions to primary myelofibrosis from mesenchymal stromal cells (MS

40 cythemia vera, essential thrombocythemia and primary myelofibrosis has diagnostic and pathogenetic im

41 ntial thrombocytosis, polycythemia vera, and primary myelofibrosis has ushered in a new era of scient

42 patients with essential thrombocythemia and primary myelofibrosis) has led the World Health Organiza

43 the bone marrow and spleen of patients with primary myelofibrosis have a mesenchymal phenotype, whic

44 rs, and potentially useful animal models for primary myelofibrosis have been developed.

45 Most patients with primary myelofibrosis have elevated levels of JAK-depend

46 Primary myelofibrosis is a myeloproliferative neoplasm t

47 We conclude that MK in primary myelofibrosis is associated with extremely poor

48 Primary myelofibrosis is characterized by the developmen

49 Primary myelofibrosis is the rarest of the myeloprolifer

50 patients with essential thrombocythemia and primary myelofibrosis, it has been hoped that targeted i

51 Among 200 patients with primary myelofibrosis, karyotype at diagnosis was abnorm

52 Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, an

53 The latter line of mice also developed primary myelofibrosis-like symptoms as they aged.

54 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF).

55 Smad2 levels were intrinsically increased in primary myelofibrosis-MSC along with enhanced expression

56 Primary myelofibrosis-MSC overexpressed heparin-binding

57 From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by

58 Primary myelofibrosis or myelofibrotic transformation pr

59 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post

60 We found a high frequency of SF3B1-mutated primary myelofibrosis patients (14%) with distinct 3' sp

61 is study, we show that bone marrow MSCs from primary myelofibrosis patients exhibit unique molecular

62 n complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment a

63 matopoietic and stromal cell compartments in primary myelofibrosis patients may heighten therapeutic

64 Among 793 primary myelofibrosis patients seen at our institution,

65 of JAK2 V617F- essential thrombocythemia and primary myelofibrosis patients, respectively, have "cano

66 The limited effects of current treatments of primary myelofibrosis (PM) led us to prospectively evalu

67 spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypi

68 Primary myelofibrosis (PMF) and polycythemia vera (PV) a

69 Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases charact

70 vera (PV), essential thombocytosis (ET), and primary myelofibrosis (PMF) as pathogenetically related

71 Treatment of polycythemia vera (PV) and primary myelofibrosis (PMF) CD34(+) cells with low doses

72 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-nega

73 er-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant

74 Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognos

75 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have been extensively review

76 Patients with primary myelofibrosis (PMF) have substantially reduced l

77 Primary myelofibrosis (PMF) is a clonal hematologic mali

78 Primary myelofibrosis (PMF) is a fatal neoplastic diseas

79 Primary myelofibrosis (PMF) is a myeloproliferative neop

80 Primary myelofibrosis (PMF) is a myeloproliferative neop

81 Primary myelofibrosis (PMF) is a myeloproliferative neop

82 Primary myelofibrosis (PMF) is characterized by bone mar

83 Primary myelofibrosis (PMF) is characterized by fibrosis

84 Primary myelofibrosis (PMF) is one of three myeloprolife

85 sporadic essential thrombocythemia (ET) and primary myelofibrosis (PMF) lacking JAK2 and MPL mutatio

86 Because primary myelofibrosis (PMF) originates at the level of t

87 system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cy

88 tional Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to pr

89 ia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whereas CALR and MPL mutants

90 ythemia (ET) compared with early/prefibrotic primary myelofibrosis (PMF) with presenting thrombocythe

91 designed to define neoplastic stem cells of primary myelofibrosis (PMF), a myeloproliferative neopla

92 e analyzed samples from patients affected by primary myelofibrosis (PMF), a well-known pathological s

93 longer duration than in patients with PV and primary myelofibrosis (PMF), and that "triple negative"

94 ntial thrombocythemia, polycythemia vera and primary myelofibrosis (PMF), are a heterogeneous group o

95 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed according to

96 s the only curative option for patients with primary myelofibrosis (PMF), but information on its net

97 ients with essential thrombocythemia (ET) or primary myelofibrosis (PMF), first investigating a cohor

98 ck of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indication

99 rotein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF).

100 era (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF).

101 ients with essential thrombocythemia (ET) or primary myelofibrosis (PMF).

102 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

103 marrow fibrosis is a maladaptive feature of primary myelofibrosis (PMF).

104 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

105 ents with essential thrombocythemia (ET) and primary myelofibrosis (PMF).

106 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

107 is a hallmark of bone marrow (BM) milieu in primary myelofibrosis (PMF).

108 es reliable risk assessment in patients with primary myelofibrosis (PMF).

109 unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF).

110 ransformation, and survival of patients with primary myelofibrosis (PMF).

111 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

112 cance for SF3B1 mutations in both MDS-RS and primary myelofibrosis (PMF).

113 enotype and progression in 499 patients with primary myelofibrosis (PMF).

114 ra (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

115 of CD34+ cells is a unique characteristic of primary myelofibrosis (PMF).

116 ot included in current prognostic scores for primary myelofibrosis (PMF).

117 oproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF): prefibrotic/early (pre-PMF)

118 es including essential thrombocythemia (ET); primary myelofibrosis (PMF); and MPN, unclassifiable (MP

119 h JAK2 V617F-positive or JAK2 V617F-negative primary myelofibrosis, post-essential thrombocythemia my

120 rrent diagnosis of intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibr

121 19 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibro

122 ythemia vera, essential thrombocythemia, and primary myelofibrosis show an inherent tendency for tran

123 the bone marrow and spleen of patients with primary myelofibrosis show functional and morphologic ch

124 source of a critical osteogenic function in primary myelofibrosis that supports its pathophysiology,

125 t patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK

126 cythemia vera, essential thrombocythemia and primary myelofibrosis, there likely are additional genet

127 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases.

128 f 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 para

129 nd extramedullary hematopoiesis characterize primary myelofibrosis, which is also associated with bon

130 t patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 and MPL.

131 g patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR

132 y acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL.